ACADIA Pharmaceuticals (ACAD) revenue breakdown
By product, NUPLAZID is the largest at 63% of fiscal 2025 revenue; DAYBUE grew fastest, 49% a year over 2 years.
Revenue by product
Fiscal years, as ACADIA Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $1.1B.
| Products | 2016 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|
| NUPLAZID | — | $549M | $609M | $680M | 63% |
| DAYBUE | — | $177M | $348M | $391M | 37% |
| Product | $17M | — | — | — | — |
| Product and Service, Other | $4,000 | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ACAD.
Open ACAD in InvestinglyQuestions
Where does ACADIA Pharmaceuticals make its money?
In fiscal 2025, by product: NUPLAZID $680M, DAYBUE $391M.
From ACADIA Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.